Sign In
Buy VERA
$31.58
-1.31 (-3.98%)
At Close: Aug 10, 2026
Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround
11:18am, Monday, 16'th Oct 2023
Vera Therapeutics, Inc. (VERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earn
Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
10:22am, Friday, 13'th Oct 2023
Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum
What Makes Vera Therapeutics, Inc. (VERA) a New Buy Stock
05:42pm, Tuesday, 15'th Aug 2023
Vera Therapeutics, Inc. (VERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vera: New Kidney Data, May Be A Potential Next Big Pharma M&A Target
09:42am, Tuesday, 04'th Jul 2023
Vera Therapeutics revealed 36-week efficacy and safety findings of its Phase IIb ORIGIN clinical study of atacicept for IgAN at the 60th European Renal Association Congress. The study met its primary
Vera: Repurposed Molecule Program Does Not Impress
01:39pm, Monday, 03'rd Jul 2023
Vera Therapeutics, Inc. is trying to develop an old molecule it licensed from Merck & Co., Inc. Trials conducted years earlier produced unimpressive results. While the company has produced some positi
Why Shares of Vera Therapeutics Jumped Tuesday
07:04pm, Tuesday, 20'th Jun 2023
The company's lead therapy, Atacicept, is faring well in a phase 2b trial. Vera Therapeutics is already recruiting patients for a phase 3 trial for Atacicept.
Vera Therapeutics shares surge on positive IgAN trial results
03:56pm, Tuesday, 20'th Jun 2023
Vera Therapeutics, Inc shares climbed 20% to $15.38 on Tuesday after the late-stage biotechnology company revealed positive trial results for atacicept, its treatment for an autoimmune disease of the
2 Surging Healthcare Stocks With More Fuel in the Tank
09:33am, Tuesday, 20'th Jun 2023
Shares of two biotech stocks are way up over the past month thanks to impressive clinical trial results for the drugs they're developing. Chinook Therapeutics has agreed to a buyout offer from Merck b
Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts say
03:40pm, Monday, 12'th Jun 2023
In light of a Novartis NVS, -0.94% deal to acquire Chinook Therapeutics Inc. KDNY, +58.09%, which is developing treatments for a rare kidney disease, two other companies focused on the same disease lo
Why Shares of Vera Therapeutics Are Soaring Monday
12:05pm, Monday, 12'th Jun 2023
Vera Therapeutics is a clinical-stage biotech. One of Vera's competitors in kidney therapies just agreed to a buyout offer from Novartis.
7 Stocks That Wall Street Analysts Are Loving in June
01:08pm, Sunday, 11'th Jun 2023
Peruse the Internet and you'll eventually see opinions deriding top analyst recommended stocks as nothing but a clown show. Sure enough, many experts do get it wrong because let's face it: if someone
Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
08:00am, Thursday, 08'th Jun 2023
BRISBANE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
Should You Buy Vera Therapeutics (VERA) Ahead of Earnings?
09:56am, Thursday, 11'th May 2023
Vera Therapeutics (VERA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Strong Small-Cap Insider Buys: Q1 2023
12:15am, Wednesday, 26'th Apr 2023
Strong Small-Cap Insider Buys: Q1 2023.
Why Vera Therapeutics Stock Bolted Higher This Week
07:39am, Sunday, 22'nd Jan 2023
Vera's stock gained a noteworthy 49% this week.
